Precision BioSciences (DTIL) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Molecular Partners (MOLN) over the past year, gaining 10.0% versus a gain of 2.7%. Over five years, MOLN leads with a -80.8% price change compared with -97.9% for DTIL. Precision BioSciences is the larger company by market cap ($172.5 million vs $145.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | MOLN |
|---|---|---|
| Share price | $6.25 | $3.81 |
| Market cap | $172.51M | $145.94M |
| 1-day change | +0.81% | +0.79% |
| YTD return | +50.24% | -12.59% |
| 1-year return | +10.04% | +2.70% |
| 5-year return | -97.87% | -80.76% |
| EPS (TTM) | $-1.35 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $5.36 |
| 52-week low | $3.53 | $3.53 |
| Distance from 52-week high | -35.03% | -28.92% |
| Analyst consensus | none | none |
| Avg. price target upside | +370.40% | +172.18% |
| Average volume | 295.49K | 1.20K |
| Shares outstanding | 27.60M | 38.31M |
| Employees | 67 | 134 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Healthcare · Biotechnology · 67 employees
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Healthcare · Biotechnology · 134 employees
DTIL vs MOLN FAQ
Which is bigger, Precision BioSciences or Molecular Partners?
Precision BioSciences (DTIL) is larger, with a market capitalization of $172.51M compared with $145.94M for Molecular Partners (MOLN).
Which stock has performed better over the past year, DTIL or MOLN?
DTIL returned +10.04% over the past 12 months, compared with +2.70% for MOLN (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.